Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) EBIT Margin: 2012-2025

Historic EBIT Margin for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to 17.40%.

  • Veracyte's EBIT Margin rose 703.00% to 17.40% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.00%, marking a year-over-year increase of 1053.00%. This contributed to the annual value of 3.62% for FY2024, which is 2738.00% up from last year.
  • According to the latest figures from Q3 2025, Veracyte's EBIT Margin is 17.40%, which was up 529.93% from -4.05% recorded in Q2 2025.
  • Veracyte's 5-year EBIT Margin high stood at 17.40% for Q3 2025, and its period low was -123.74% during Q1 2021.
  • Over the past 3 years, Veracyte's median EBIT Margin value was -4.05% (recorded in 2025), while the average stood at -5.82%.
  • As far as peak fluctuations go, Veracyte's EBIT Margin plummeted by 8,454bps in 2021, and later spiked by 10,124bps in 2022.
  • Quarterly analysis of 5 years shows Veracyte's EBIT Margin stood at -18.32% in 2021, then spiked by 1,157bps to -6.75% in 2022, then slumped by 2,941bps to -36.16% in 2023, then surged by 3,968bps to 3.52% in 2024, then spiked by 703bps to 17.40% in 2025.
  • Its EBIT Margin stands at 17.40% for Q3 2025, versus -4.05% for Q2 2025 and 2.54% for Q1 2025.